New Hepatitis C Treatment Approved by FDA: Mavyret
Description:
Mavyret is made up of two hepatitis C treatments glecaprevir and pibrentasvir, taken as three pills together once a day. Mavyret is used to treat hepatitis C by AbbVie. – PowerPoint PPT presentation
Title: New Hepatitis C Treatment Approved by FDA: Mavyret
1 New Hepatitis C Treatment Approved by FDA Mavyret 2
Mavyret is used to treat hepatitis C by AbbVie.
Mavyret is an 8 week treatment for all genotypes of hepatitis C.
Mavyret cost for, 8 week course, 56 tablets is only 26,400.For 12 weeks treatment 39,600, 16 weeks treatment 52,800.
Mavyret is more affordable than Sovaldi, Harvoni, Epclusa and Daklinza.
3
AbbVie will focus on getting insurers to only provide Mavyret rather than the competitors. It will do this by providing 50 off on treatment costs.
AbbVie will also focus on getting coverage for Medicare, Medicaid and the Veterans Administration.
Clinical study show for Mavyret that 97.5 of adult patients are cured, only those without cirrhosis. 98 of those with kidney damage were cured after 12 weeks of treatment.
4
Mavyret is made up of two hepatitis C treatments glecaprevir and pibrentasvir, taken as three pills together once a day.
Mavyret side effects were nausea, fatigue, headache and itchy skin.
Hepatitis B patients that also have hepatitis C that take Mavyret can reactivate that virus causing fatal liver damage.